Crossmark

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

Crossref DOI link: https://doi.org/10.1016/j.rppnen.2016.03.009

Published Print: 2016-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Barata, F.

Queiroga, H.

Teixeira, E.

Almodovar, M.T.

Parente, B.

Soares, M.
Funding

Funding for this research was provided by:

Roche Farmacêutica Química, Lda
License Information

Text and Data Mining valid from 2016-09-01

Version of Record valid from 2016-04-08
More Information

This article is maintained by: Elsevier

Article Title: MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

Journal Title: Revista Portuguesa de Pneumologia (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rppnen.2016.03.009

Content Type: simple-article

Copyright: © 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below